logo
Plus   Neg
Share
Email

Jazz Pharma: FDA Grants Priority Review For Lurbinectedin

PharmaMar and Jazz Pharmaceuticals plc (JAZZ) announce that a New Drug Application for Lurbinectedin has been accepted by FDA and granted Priority Review for Relapsed Small Cell Lung Cancer.

The Priority Review by the FDA is for patients with Small Cell Lung Cancer (SCLC) who have progressed after prior platinum-containing therapy.

A Prescription Drug User Fee Act or PDUFA date is set for August 16, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
RELATED NEWS
Follow RTT
>